glp-1 crohn's disease and Adjunctive GLP1 Receptor Agonists in Patients With Inflammatory Bowel Diseases Obesity and/or Diabetes: A Target Trial Emulation GLP-1 and Crohn's Disease: Safety – GLP-1 Use in Crohn's Disease:

Rahman I, Kode A, Biswas SK

The manual's section 10.1 sets the pairing rule clearly: use Lumo+ before microinfusion on the same session day (warms tissue, primes circulation), wait at least 24 hours after microinfusion before resuming any RF or EMS device (heat on freshly opened channels amplifies redness and disturbs early healing), and use Lumo+ on its normal schedule of 3 to 5 sessions per week on non-microinfusion days

S-nitrosoglutathione (GSNO), a nitrosylated derivative, demonstrates enhanced wound healing properties

Priority research needs include large-scale randomized controlled trials to establish efficacy and safety, dose-ranging studies to optimize treatment protocols, long-term safety studies particularly regarding cancer risk, and comparative effectiveness research with established therapies